Earnings call transcript: Sensus Healthcare misses Q1 2026 forecasts

Sensus Healthcare reported Q1 2026 EPS of -$0.16 versus -$0.13 expected and revenue of $3.4 million versus $5.34 million expected, with revenue down 59% year over year and gross margin compressing to 29.2% from 52.2%. Management said the largest customer remains excluded from the 2026 model, but highlighted new CPT codes, improving reimbursement, and the rollout of Sensus Link as drivers for second-half growth and eventual profitability. Shares rose 1.22% to $4.09 after the release, suggesting a muted market reaction to the miss.

Analysis

The near-term winner is not SRTS’s P&L; it is the reimbursement ecosystem around dermatology SRT adoption. Dedicated codes lower the “decision friction” for physicians and billers, which should compress sales cycles over the next 1-2 quarters, but the bigger effect is on competitive positioning: smaller device makers without an attached reimbursement narrative will struggle to win budget share against a now-financeable workflow. The channel shift toward ownership and financing also means revenue recognition will lag unit activity, so headline growth may understate underlying demand for several quarters.

The market is likely underappreciating the mix transition risk. If higher utilization shifts toward recurring software/service revenue, gross margin can recover, but in the interim the company is absorbing a double hit: upfront shipment revenue is being replaced by deferred economics while service-enabled installs carry lower initial margins. That creates a window where reported revenue can look weak even as pipeline and installed base economics improve, which is exactly the kind of setup that can support a rally on better-than-feared guide, then a second leg only when repeatable utilization data appears.

Contrarian angle: the consensus seems to assume the old anchor customer is gone and won’t matter, but that customer was also masking the true optionality of the model. If the new reimbursement proof points drive even modest adoption across larger dermatology roll-ups, the incremental revenue per installed system could scale faster than modeled, because the billing code economics now create a software-led attach opportunity. The key risk is execution timing: if EOB proof doesn’t translate into bookings by late Q2/early Q3, investors will start treating the “future growth” narrative as another long-dated story rather than a 2026 catalyst.

Key Decisions for Investors

• Long SRTS common on weakness for a 3-6 month horizon; treat sub-$4.00 as accumulation area, with upside to the $6-$8 analyst range if Q2 shows booking conversion and not just pipeline growth. Risk: another quarter of deferred-revenue optics without unit acceleration.
• Buy SRTS Jan-2027 out-of-the-money calls or call spreads to express the adoption inflection with defined downside; the thesis depends on utilization and Sensus Link attach rates compounding into 2026. Risk/reward is attractive if the stock rerates on recurring-revenue visibility.
• Pair trade: long SRTS / short a broader med-tech name with less reimbursement leverage over the next 1-2 quarters. The spread should widen if SRTS benefits from a unique policy catalyst while peers remain macro-driven. Risk: SRTS execution disappointment or a broader de-risking tape.
• If looking for a tactical trade, wait for the next conference/industry-event driven bounce to fade and re-enter after the market can verify EOB-driven conversion. This is a better setup for swing longs than chasing the immediate post-earnings move.